| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Evgen Pharma recruits first patient in study to assess acute respiratory infections drug
StockMarketWire.com
|
Drug development company Evgen Pharma said it had enrolled and dosed its first patient in the STAR trial evaluating SFX-01 as a treatment for acute respiratory infections.
This phase II/III trial would investigate whether the Company's lead asset, SFX-01, 'can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with community-acquired pneumonia who have been or are being tested for suspected COVID-19,' the company said.
'We remain hopeful that the outcome of this trial will reduce both the severity and duration of the disease for COVID-19 patients and those with pneumonia from other infective agents,' it added.
At 9:47am: (LON:EVG) Evgen Pharma Plc share price was 0p at 8.3p
Story provided by StockMarketWire.com
|
|
|
|
|
|
